LIA
LGND icon

Luken Investment Analytics’s Ligand Pharmaceuticals LGND Stock Holding History

Luken Investment Analytics’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50
Closed -$3.57K – 133
2023
Q4 		$3.57K Hold
50
– – ﹤0.01% 122
2023
Q3 		$3K Sell
50
-50
-50% -$3.29K ﹤0.01% 131
2023
Q2 		$7.21K Hold
100
– – ﹤0.01% 124
2023
Q1 		$7.36K Hold
100
– – ﹤0.01% 117
2022
Q4 		$6.68K Buy
+100
New +$6.5K ﹤0.01% 118
2020
Q4 		$10K Buy
+160
New +$9.12K 0.01% 84

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Luken Investment Analytics's LGND Position: Q1 2024 in Review

Luken Investment Analytics sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 50 shares — an estimated $3.57K sold.

Luken Investment Analytics first reported a position in LGND in Q4 2020 and held it in 6 quarters. The position peaked at $10K in Q4 2020. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • Luken Investment Analytics reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Luken Investment Analytics sold 50 Ligand Pharmaceuticals shares in Q1 2024, an estimated $3.57K.
  • Luken Investment Analytics first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Luken Investment Analytics's Ligand Pharmaceuticals position peaked at $10K in Q4 2020.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Luken Investment Analytics's 13F filing for Q1 2024, filed 23 Apr 2024.